. Author manuscript; available in PMC: 2017 Aug 14.

Published in final edited form as: Tetrahedron. 2017 Mar 6;73(16):2234–2241. doi: 10.1016/j.tet.2017.03.003

Table 3.

Bioactivities for compounds 1–8 against HCT-116 human colon carcinoma, the bacterium Staphylococcus aureus, and the pathogenic yeast Candida albicans.

Compound	HCT-116, IC₅₀ (μM)	Staphylococcus aureus MIC (μM)	Candida albicans MIC (μM)
1	0.049	2.37	0.95
2	0.029	33.92	5.79
3	0.078	30.71	3.90
4	10.56	36.62	14.67
5	7.28	36.62	14.67
6	17.14	36.62	14.67
7	2.92	56.93	114.2
8	2.41	2.92	5.96

The MIC of vancomycin is 0.27 μM for S. aureus and the MIC of amphotericin B is 0.084 μM for C. albicans.